Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA ConferenceFirst-of-its-Kind Pivotal Study of the Tack Endovascular System® Demonstrates 100% Dissection Resolution in Challenging Below-the-Knee Disease

November 6, 2019 – WAYNE, Pa.–(BUSINESS WIRE)– Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the positive six-month results of its Tack Optimized Balloon Angioplasty (TOBA) II BTK clinical trial, successfully achieving all primary (P < 0.0001) and secondary endpoints with very low rates of major amputation …

Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA ConferenceFirst-of-its-Kind Pivotal Study of the Tack Endovascular System® Demonstrates 100% Dissection Resolution in Challenging Below-the-Knee Disease Read More »